Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19
Copyright © 2022. Published by Elsevier B.V..
BACKGROUND: Patients recovering from COVID-19 may need vaccination against SARS-CoV-2 because acquired immunity from primary infection may wane, given the emergence of new SARS-CoV-2 variants. Understanding the trends of anti-spike IgG and neutralizing antibody titers in patients recovering from COVID-19 may inform the decision made on the appropriate interval between recovery and vaccination.
METHODS: Participants aged 20 years or older and diagnosed with COVID-19 between January and December, 2020 were enrolled. Serum specimens were collected every three months from 10 days to 12 months after the onset of symptom for determinations of anti-spike IgG and neutralizing antibody titers against SARS-CoV-2 Wuhan strain with D614G mutation, alpha, gamma and delta variants.
RESULTS: Of 19 participants, we found a decreasing trend of geometric mean titers of anti-spike IgG from 560.9 to 217 and 92 BAU/mL after a 4-month and a 7-month follow-up, respectively. The anti-spike IgG titers declined more quickly in the ten participants with severe or critical disease than the nine participants with only mild to moderate disease between one month and seven months after SARS-CoV-2 infection (-8.49 vs - 2.34-fold, p < 0.001). The neutralizing activity of the convalescent serum specimens collected from participants recovering from wild-type SARS-CoV-2 infection against different variants was lower, especially against the delta variants (p < 0.01 for each variant with Wuhan strain as reference).
CONCLUSION: Acquired immunity from primary infection with SARS-CoV-2 waned within 4-7 months in COVID-19 patients, and neutralizing cross-activities against different SARS-CoV-2 variants were lower compared with those against wild-type strain.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:122 |
---|---|
Enthalten in: |
Journal of the Formosan Medical Association = Taiwan yi zhi - 122(2023), 8 vom: 09. Aug., Seite 714-722 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Liu, Wang-Da [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Neutralizing |
---|
Anmerkungen: |
Date Completed 17.07.2023 Date Revised 18.07.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.jfma.2022.11.015 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM350085064 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM350085064 | ||
003 | DE-627 | ||
005 | 20231226044142.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jfma.2022.11.015 |2 doi | |
028 | 5 | 2 | |a pubmed24n1166.xml |
035 | |a (DE-627)NLM350085064 | ||
035 | |a (NLM)36496300 | ||
035 | |a (PII)S0929-6646(22)00436-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Liu, Wang-Da |e verfasserin |4 aut | |
245 | 1 | 0 | |a Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19 |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 17.07.2023 | ||
500 | |a Date Revised 18.07.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2022. Published by Elsevier B.V. | ||
520 | |a BACKGROUND: Patients recovering from COVID-19 may need vaccination against SARS-CoV-2 because acquired immunity from primary infection may wane, given the emergence of new SARS-CoV-2 variants. Understanding the trends of anti-spike IgG and neutralizing antibody titers in patients recovering from COVID-19 may inform the decision made on the appropriate interval between recovery and vaccination | ||
520 | |a METHODS: Participants aged 20 years or older and diagnosed with COVID-19 between January and December, 2020 were enrolled. Serum specimens were collected every three months from 10 days to 12 months after the onset of symptom for determinations of anti-spike IgG and neutralizing antibody titers against SARS-CoV-2 Wuhan strain with D614G mutation, alpha, gamma and delta variants | ||
520 | |a RESULTS: Of 19 participants, we found a decreasing trend of geometric mean titers of anti-spike IgG from 560.9 to 217 and 92 BAU/mL after a 4-month and a 7-month follow-up, respectively. The anti-spike IgG titers declined more quickly in the ten participants with severe or critical disease than the nine participants with only mild to moderate disease between one month and seven months after SARS-CoV-2 infection (-8.49 vs - 2.34-fold, p < 0.001). The neutralizing activity of the convalescent serum specimens collected from participants recovering from wild-type SARS-CoV-2 infection against different variants was lower, especially against the delta variants (p < 0.01 for each variant with Wuhan strain as reference) | ||
520 | |a CONCLUSION: Acquired immunity from primary infection with SARS-CoV-2 waned within 4-7 months in COVID-19 patients, and neutralizing cross-activities against different SARS-CoV-2 variants were lower compared with those against wild-type strain | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a B.1.617.2 | |
650 | 4 | |a Delta variant | |
650 | 4 | |a Humoral immunity | |
650 | 4 | |a Plaque reduction neutralization test (PRNT) | |
650 | 4 | |a Spike protein | |
650 | 4 | |a Variant of concern | |
650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
650 | 7 | |a Immunoglobulin G |2 NLM | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
700 | 1 | |a Wang, Jann-Tay |e verfasserin |4 aut | |
700 | 1 | |a Chao, Tai-Ling |e verfasserin |4 aut | |
700 | 1 | |a Ieong, Si-Man |e verfasserin |4 aut | |
700 | 1 | |a Tsai, Ya-Min |e verfasserin |4 aut | |
700 | 1 | |a Kuo, Po-Hsien |e verfasserin |4 aut | |
700 | 1 | |a Tsai, Ming-Jui |e verfasserin |4 aut | |
700 | 1 | |a Chen, Yi-Jie |e verfasserin |4 aut | |
700 | 1 | |a Li, Guei-Chi |e verfasserin |4 aut | |
700 | 1 | |a Ho, Shu-Yuan |e verfasserin |4 aut | |
700 | 1 | |a Chen, Hui-Hou |e verfasserin |4 aut | |
700 | 1 | |a Huang, Yu-Shan |e verfasserin |4 aut | |
700 | 1 | |a Hung, Chien-Ching |e verfasserin |4 aut | |
700 | 1 | |a Chen, Yee-Chun |e verfasserin |4 aut | |
700 | 1 | |a Chang, Sui-Yuan |e verfasserin |4 aut | |
700 | 1 | |a Chang, Shan-Chwen |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of the Formosan Medical Association = Taiwan yi zhi |d 1992 |g 122(2023), 8 vom: 09. Aug., Seite 714-722 |w (DE-627)NLM012627941 |x 0929-6646 |7 nnns |
773 | 1 | 8 | |g volume:122 |g year:2023 |g number:8 |g day:09 |g month:08 |g pages:714-722 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jfma.2022.11.015 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 122 |j 2023 |e 8 |b 09 |c 08 |h 714-722 |